Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04366518 · ClinicalTrials.gov registry record · Early Phase 1
Toward a Computationally-Informed, Personalized Treatment for Hallucinations
A Early Phase 1 study of Psychosis and Hallucinations, Auditory, sponsored by Yale University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT04366518 is a Early Phase 1 study of Psychosis and Hallucinations, Auditory that is actively recruiting participants, run by Yale University. The registered enrollment target is 35 participants, below the 178-participant average among 35 other Psychosis trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04366518, a Early Phase 1 study of Psychosis and Hallucinations, Auditory, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manipulation of relevant model parameters underlying these phenomena.
Conditions Studied
Interventions
- DRUG Placebo Patch
- DRUG Rivastigmine Transdermal System
- DRUG Scopolamine
Study Locations (1)
Connecticut
- Connecticut Mental Health Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2032-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04366518
The ClinicalTrials.gov registry entry for NCT04366518 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 35 other Psychosis trials with a reported enrollment target (80% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Psychosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo Patch is the first listed.
NCT04366518 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT04366518 about?
NCT04366518 is a clinical study titled "Toward a Computationally-Informed, Personalized Treatment for Hallucinations". Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinat...
What is the current status of trial NCT04366518?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 35 participants. The study started on 2021-07-15. Estimated completion is 2032-08.
What conditions does trial NCT04366518 study?
This clinical trial studies the following conditions: Psychosis, Hallucinations, Auditory.
What interventions are being tested in trial NCT04366518?
The interventions under investigation include: Placebo Patch (DRUG), Rivastigmine Transdermal System (DRUG), Scopolamine (DRUG).
Who is sponsoring clinical trial NCT04366518?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04366518 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psychosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Probing the Cannabinoid System in Individuals With a Family History of Psychosis
ACTIVE NOT RECRUITING · Early Phase 1
-
A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults
RECRUITING · NA
-
Determining the Role of Social Reward Learning in Social Anhedonia
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia
RECRUITING · NA
-
Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.